| Oct 9 |
Eyenovia Inc (EYEN) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
|
| Oct 1 |
Eyenovia (EYEN) files for $100M mixed shelf offering
|
| Oct 1 |
Eyenovia Announces Commencement of Manufacturing of its Advanced, Second Generation Optejet Device
|
| Sep 27 |
Eyenovia stock slides on pricing capital raise of about $4 million via securities offering
|
| Sep 27 |
Eyenovia, Inc. Announces Pricing of $4 Million Registered Direct Offering
|
| Sep 26 |
Eyenovia announces commercial availability of clobetasol, shares rise
|
| Sep 26 |
Eyenovia Announces Launch and Commercial Availability of Clobetasol Propionate Ophthalmic Suspension 0.05% for Post-Operative Inflammation and Pain Following Ocular Surgery
|
| Sep 9 |
Formosa Pharma ships APP13007 ophthalmic drug to US
|
| Sep 5 |
Eyenovia Announces Taiwan Export License Approval to Commence Shipment of Clobetasol Propionate Ophthalmic Suspension (0.05%) to the U.S.
|
| Sep 3 |
Eyenovia appoints Andrew Jones as CFO
|
